NeoGenomics Launches Immuno-Oncology Companion Diagnostic Test for Triple Negative Breast Cancer in Conjunction with FDA Approval for TECENTRIQ(R) Mar 11, 2019
NeoGenomics Reports Record Revenue of $76 Million with 17% Organic Revenue Growth in the Fourth Quarter Feb 19, 2019
NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2018 Earnings Release for February 19, 2019 Jan 28, 2019
